In addition, subgroup analysis found that fetuin-A concentrations were significantly higher in the NAFL patients than in the controls, with high effect (SMD = 0.65, 95% CI: 0.39 to 0.90, p < 0.001); and in the NASH patients than in the controls, with high effect (SMD = 1.30, 95% CI: 0.74 to 1.86, p < 0.001), but both with high heterogeneity (I2 = 90.0% and 91.8%, respectively). This evidence concerns the gene AHSG and metabolic dysfunction-associated steatohepatitis.